TrialFrontiers in immunology2026

Tislelizumab combined with gemcitabine as first-line treatment in cisplatin-ineligible patients with locally advanced or metastatic urothelial carcinoma: a single center, single-arm phase 2 trial.

Mengyao Liu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.